EFFECTIVENESS OF BLOCKERS OF THE MINERALOCORTICOID RECEPTORS (SPIRONOLACTONE, EPLERENONE) IN CHRONIC HEART FAILURE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article discusses the effectiveness and safety of the mineralocorticoid receptors blockers, spironolactone and eplerenone (Espiro) in the treatment of patients with chronic heart failure (CHF). We consider the importance of early diagnosis of chronic circulatory failure and methods used for this. We present the results of major international clinical trials evaluating spironolactone and eplerenone, as well as indications and contraindications of their prescription. The results clearly showed that adding mineralocorticoid receptors inhibitors to the standard therapy of patients with chronic heart failure (ACE inhibitors, angiotensin receptor blockers II, β-blockers, diuretics) significantly increase the effect of the treatment, improve hemodynamics, quality of life and reduce the mortality rate of patients.

Full Text

Restricted Access

About the authors

Viktor Vladimirovich Cheltsov

Medical Centre of Moscow Mayor and Government Affairs

Email: vcheltsov@mail.ru

Anatoly Ivanovich Martynov

Medical Faculty of A.I. Evdokimov Moscow State Medical and Dental University

Email: mailbox@rnmot.ru

References

  1. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., Falk V., Filippatos G., Fonseca C., Gomez-Sanchez M.A., Jaarsma T., Køber L., Lip G.Y., Maggioni A.P., Parkhomenko A., Pieske B.M., Popescu B.A., Rønnevik P.K., Rutten F.H., Schwitter J., Seferovic P., Stepinska J., Trindade P.T., Voors A.A., Zannad F., Zeiher A.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012,33:1787-847.
  2. Федеральные клинические рекомендации по диагностике и лечению хронической и острой сердечной недостаточности. М., 2013
  3. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН. Сердечная недостаточность. 2004;5(1):4-7.
  4. Heidenreich P.A., Albert N.M., Aller L.A. et al. American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United State: a policy statement from the American Heart Association. Cire. Heart Fail. 2013;6(3):606-9.
  5. Hunt S.A., Baker D.W., Chin M.H. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. Circulation. 2001;104:2996-3007.
  6. Cohn J.N., Archibald D.G., Ziesche S., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Dunkman W.B., Jacobs W., Francis G.S., Flohr K.H., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N. Engl. J. Med. 1986;314:1547-52.
  7. Francis G.S. Neurohormonal control of heart failure. Clev. Clin. J. Med. 2011;78(Suppl 1):75-9.
  8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Engl. J. Med. 1991;325:293-302.
  9. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W.B., Loeb H., Wong M. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 1991,32:303-10.
  10. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992;327:685-91.
  11. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch. Intern. Med. 1993;153:937-42.
  12. Jilma B., Krejcy K., Dirnberger E., Eichler H.G., Kapiotis S., Dorner G.T., Wagner O.F. Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci. 1997;60:1859-66.
  13. Kawamura M., Imanashi M., Matsushima Y., Ito K, Hiramori K. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin. Exp. Pharmacol. Physiol. 1992;19:547-53.
  14. Jorde U.P., Ennezat P.V., Lisker J., Suryadevara V., Infeld J., Cukon S., Hammer A., Sonnenblick E.H., Le Jemtel T.H. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000;101:844-6.
  15. Con J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001;345:1667-75.
  16. Struthers A.D., MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc. Rev. 2004;61:663-70.
  17. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-6.
  18. Cicoira M., Zanolla L., Franceschini L., Rossi A, Golia G, Zeni P., Caruso B., Zardini P. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2002;89:403-7.
  19. Bomback A.S., Klemmer P.J. The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 2007;3:9:486-92.
  20. Staessen J., Lijnen P., Fagard R., Verschueren L.J, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol. 1981;91:457-65.
  21. Tang W.H., Vagelos R.H., Yee Y.G., Benedict C.R., Willson K., Liss C.L., Fowler M.B. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J. Am. Coll. Cardiol. 2002;39:70-8.
  22. McKelvie R.S., Yusuf S., Pericak D., Avezum A., Burns R.J., Probstfield J., Tsuyuki R.T., White M., Rouleau J., Latini R., Maggioni A., Young J., Pogue J. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 1999;100:1056-64.
  23. Silvestre J.S., Robert V., Heymes C., Aupetit-Faisant B., Mouas C., Moalic J.M., Swynghedauw B., Delcayre C. Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J. Biol. Chem. 1998;273:4883-91.
  24. Gomes-Sanchez C.E., Zhou M.Y., Cozza E.N. Aldosterone biosynthesis in the rat brain. Endocrinology. 1997;138:3369-73.
  25. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on mor bidity and mortality in patients with severe heart faire. N. Engl. J. Med. 1999;341:709-17.
  26. Cicoira M., Zanolla L., Rossi A., Golia G., Franceschini L., Brighetti G., Marino P., Zardini P. Long-term, dose-dependent effects of spironolactone on left function and exercise tolerance in patients with chronic heart failure. J. Am. Coll. Cardiol. 2002;40:304-10.
  27. Cook C.S., Berry L.M., Bible R.H., Hribar J.D., Hajdu E., Liu N.W. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab. Dispos. 2003;31(11):1448-55.
  28. Cook C.S., Berry L.M., Kim D.H., Burton E.G., Hribar J.D., Zhang L. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab. Dispos. 2002;30(12):1344-51.
  29. McManus F., McInnes G.T., Connell J.M. Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nat. Clin. Pract. Endocrinol. Metab. 2008;4(1):44-52.
  30. Delyani J.A., Rocha R., Cook C.S., Tobert D.S., Levin S., Roniker B., Workman D.L., Sing Y.L., Whelihan B. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc. Drug Rev. 2001;19:185-200.
  31. Sanz-Rosa D., Oubina M.P., Cediel E., De las Heras N., Aragoncillo P., Balfagân G., Cachofeiro V., Lahera V. Eplerenone reduced oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid. Redox. Signal. 2005;7(9-10):1294-301.
  32. Pitt B., Remme W., Zannad F., Pitt B., Remme W., Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEJM. 2003;348:1309-21.
  33. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Vincent J., Pocock S.J., Pitt B.; EMPHASISHF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011;36(4):11-21.
  34. Deswal A., Richardson P., Bozkurt B., Mann D.L. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J. Card. Fail. 2011;17(8):634-42.
  35. Wilson Tang W.H., Marcy T.R., Ripley T.L. Aldosterone antagonists in the treatment of heart failure. Am. J. Health Syst. Pharm. 2006;63(1):49-58.
  36. Miller A.B. Aldosterone antagonism in heart failure. Vasc. Health Risk Manag. 2007;3(5):605-9.
  37. www.fda.gov
  38. Prisant L.M., Chin E. Gynecomastia and hypertension. J. Clin. Hypertens. (Greenwich). 2005;7(4):245-8.
  39. Rastogi S., Rodriguez J.J., Kapur V., Schwarz E.R. Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. Int. J. Impot. Res. 2005;17:25-36.
  40. Mandras S.A., Uber P.A., Mehra M.R. Sexual activity and chronic heart failure. Mayo Clin. Proc. 2007;82(10):1203-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies